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aggressive NHL, at a reasonable cost, in the perspective of the
Italian NHS.
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OBJECTIVE: To determine the incremental cost-effectiveness
ratio (ICER) of imatinib versus IFN-a + Ara-C in newly diag-
nosed, chronic phase CML patients. METHODS: An economic
simulation model was developed in Microsoft Excel to estimate
expected total cost, survival and quality-adjusted survival for
patients treated with imatinib or IFN-a + Ara-C. This model is
based on data collected in the International Interferon versus
StI571 Study (IRIS) supplemented with data from international
literature and clinical experts. This model was adapted to the
Dutch situation. Utility weights and unit costs for medical
resources were assigned over time according to disease status and
treatment regimen. Long-term survival estimation was based on
historical relationships between cytogenetic response and life
expectancy with IFN-a. The analysis incorporated ﬁrst-order
and second-order uncertainty. Sensitivity analyses were also per-
formed to evaluate the inﬂuence of individual parameters. The
base year for the cost analysis was 2002 and only direct medical
costs were considered. RESULTS: Mean undiscounted survival
for patients receiving imatinib was estimated to be 15.20 years,
for the IFN-a + Ara-C patients this was 9.10 years. When both
costs and effects were discounted at 4% the incremental gain in
quality adjusted life years (QALYs) was 3.36. Incremental dis-
counted lifetime costs were €150,041 higher for patients receiv-
ing imatinib. This resulted in an ICER of 44,728€ per QALY
(95% conﬁdence interval; 41,044€, 49,505€). These results were
most sensitive to assumptions that affected relative duration and
costs of IFN-a or imatinib. CONCLUSION: The introduction
of imatinib as ﬁrst line treatment option results in a gain of 3.36
QALYs. However, this occurred at a considerable cost resulting
in an ICER of 44,728€ per QALY. In general, this ratio is con-
sidered to be high by Dutch registration and reimbursement
authorities. However, in the process of registration and reim-
bursement other aspects like budget impact and disease severity
also play an important role.
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OBJECTIVES: Patients with pain due to multiple bone metas-
tases who do not show satisfactory response to conventional
pain therapy radionuclide therapy leads to a pain reduction in
about 70–80% of patients. The objective here is to determine
cost-effectiveness ratios for this pain reduction in Germany.
METHODS: Based on the results of a double-blind, randomized,
placebo-controlled trial with 141 prostate cancer patients
radionuclide therapy is compared with conventional pain
therapy in an economic model considering German data from
literature and treatment recommendations. Incremental cost-
effectiveness is presented. The effectiveness is measured by “com-
plete pain response”. The model period is 16 weeks. Costs from
the perspective of the statutory health insurance, i.e. deducting
co-payments and discounts, are also considered. Sensitivity
analyses are conducted. RESULTS: The direct medical costs of
radionuclide therapy per patient (39% complete pain response)
sum up to 1990€ against 2200€ under conventional pain therapy
(17% complete pain response). Radionuclide therapy is domi-
nant. From sickness fundsx perspective the costs of radionuclide
therapy sum up to 1890€ compared to 1870€ under conventional
pain therapy. The incremental cost-effectiveness-ratio is 130€ per
complete pain responder. Sensitivity analyses reveal that the
exclusion of bisphosphonates from conventional pain therapy
lead to costs of therapy of 1170€. The respective incremental
cost-effectiveness-ratio is 3800€. From sickness funds’ perspec-
tive the costs of conventional pain therapy sum up to 990 EUR.
The respective incremental cost-effectiveness-ratio is 4210€.
CONCLUSIONS: Analgesia in patients with pain due to multi-
ple bone metastases is achieved at lower or nearly equal costs
under samarium in the base case. On the basis of this model
samarium could be a cost-effective treatment option for patients
with pain due to multiple bone metastases. However, to compare
cost-effectiveness ratios with other treatment options further
research is warranted.
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OBJECTIVE: To estimate the annual cost of managing dry eye
syndrome in secondary care in France, Germany, Italy, Spain,
Sweden and the UK from the perspective of the health care
system. METHODS: Published evidence on the epidemiology of
dry eye syndrome and associated resource use were collected.
This was supplemented with information on current clinical
practice and associated resource utilisation obtained by inter-
viewing specialists in the treatment of dry eye syndrome in each
country. National unit resource costs (in Euros at 2003/04 prices)
were applied to the resource use estimates to estimate the annual
secondary care cost. RESULTS: The estimated prevalence of dry
eye syndrome among patients reporting to specialists was great-
est in Germany (0.07%) and lowest in Sweden (0.02%). An esti-
mated 70% of sufferers were female in all six countries except
Germany (58% of sufferers). Proportionally more patients expe-
rienced mild dry eye syndrome in Germany (60% of sufferers),
whereas more patients experienced moderate and severe dry eye
syndrome in France (65% of sufferers). The total annual health-
care cost fo managing 1000 dry eye syndrome sufferers in sec-
ondary care ranged from 227,000€ in France to 915,000€ in the
UK. The cost per patient was highest in the UK due to the high
cost of prescriptions. Specialist visits were the main cost driver
in France and Spain, whereas it was prescriptions in Germany
and the UK and diagnostic tests in Italy and Sweden. A large
proportion of patients either self-treat or are managed by their
GP. Hence, our analysis reﬂects the prevalence and costs of those
patients severe enough to warrant treatment by a specialist.
CONCLUSIONS: Dry eye syndrome does not appear to impose
any signiﬁcant burden on the secondary healthcare providers in
the countries investigated.
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